NCT03562871 - IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC | Biotech Hunter

Enrollment

109

Participants

Timeline

Start Date

August 22, 2018

Primary Completion Date

February 6, 2021

Study Completion Date

April 12, 2022

Conditions

NSCLC

Interventions

BIOLOGICAL

IO102

test immunotherapy

BIOLOGICAL

pembrolizumab (Keytruda)

anti-PD-1 immunotherapy

DRUG

Carboplatin (Carboplatin Kabi)

chemotherapy

DRUG

Pemetrexed (Pemetrexed Alvogen)

chemotherapy

Trial Locations (13)

17007

Hospital Universitari de Girona Doctor Josep Trueta, Girona

26121

PIUS Hospital Oldenburg, Oldenburg

28041

Hospital Universitario 12 Octubre, Madrid

28050

Hospital Universitario HM Sanchinarro, Madrid

28134

Hospital Universitario Ramón y Cajal, Madrid

29010

Servicio de Oncología-El médico del Virgen de la Victoria, Málaga

46010

Hospital Clinico Universitario de València, Valencia

69126

Thoraxklinik Heidelberg gGmbH, Heidelberg

Unknown

Stichting Het Nederlands Kanker Instituut, Amsterdam

Hospital Puerta del Hierro Majadahonda, Madrid

08028

Insituto Oncologico Dr Rosell. Hospital Universitario Quiron Dexeus, Barcelona

08035

Hospital Universitario de Vall d'Hebron, Barcelona

SE1 9RT

Guy's Hospital, London